713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial
Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre), Bo Gao(Sun Yat-sen University), Dawn Thomas(Garvan Institute of Medical Research), Damien Kee(Peter MacCallum Cancer Centre), Jonathan Cebon(La Trobe University), Yoland Antill(Peninsula Health), W-S. Lam(Fiona Stanley Hospital), Henry Chan(Calvary Mater Newcastle Hospital), M. Michael(Peter MacCallum Cancer Centre), Jamie Palmer(Olivia Newton-John Cancer Wellness & Research Centre), Jimmy Bok Yan So(National University of Singapore), Matteo S. Carlino(The University of Sydney), Anthony J Hamilton(Peter MacCallum Cancer Centre), Craig Underhill(AstraZeneca (United Kingdom)), Ken Wilkie(Olivia Newton-John Cancer Wellness & Research Centre), Rosemary Harrup(University of Tasmania)
Cited by 11
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k